Taxus Cardium Pharmaceuticals Group Inc (CE) (CRXM) Noticias

I was told to expect CR to respond to the SEC. Apparently he did not.

I'm not sure if CRXM even exists as a company at this point.

I am extremely disappointed in the CRXM management team for not communicating an update with shareholders.

https://www.sec.gov/files/litigation/opinions/2024/34-101312.pdf

When did CRXM disappear from OTC, anyone else unable to search the ticker?

I’m giving up my moderator position here on the CRXM board. Anyone interested in jumping in is welcome to do so.

Best to you all.

why they updare website it s donw ????

i m mostly ao sad trial was allmost done shareholder loose and people loose amazing that no financong or whatever

Does anyone know if a new entity has been formed and if our CRXM common shares affords us an ownership interest is this new entity?

OTC Markets didn't find anything for CRXM when I checked. Given the SEC's latest letter to Gene Bio, can't say I am surprised. I will say I'm disappointed in CR at the moment. The least he could do is put a banner on the company website providing some clarity on where things stand. Chris, do the right thing and give shareholders an update!

See Altitrade post 9/6/24.....They believe we have shares in what will become a private company.....Hopefully they raise the $ for the Phase 3 Generx Trial

yeah but crxm have been delister so our story is over

The CEO picked bad partners with Nostrum.....Now trying to raise $20,000,000 for Phase 3 Generx trial....How about getting a real deal Biotech involved.....CRXM has to get Nostrum out of the picture!

difficult to understand that crxm saga didn t continue to last trial

so we are delisted now

CRXM SEC registration revoked:

https://www.sec.gov/files/litigation/opinions/2024/34-101312.pdf

Any information on how much success there has been raising money for the trial?

I’m not sure about trading again. It will require a huge investment to get current. Unless CR has come up with another project to pursue that being a public traded company would be of benefit. Or another indication for Generx that gets carved out from the hoped for trial and new investors.

Spoken to Rinehardt a few times over the last few months . He always says he’s working on it . If we trade again it will sky rocket .

tick tock bit when boom it s big question if never

Altitrade....Appreciate your take on the situation....We have to hope for the best

only i ll can tell it s amazing that they don t have get money injection from some big pharma

It depends on three things:

1. They can obtain funding for a Phase 3 clinical trial of GeneRx.
2. They get a favorable outcome and FDA approval of the drug.
3. They can attract a Big Pharma company to purchase the drug.

I doubt that this company's shares will ever trade again. Instead, CRXM will likely implement an exit strategy for its shareholders based on the above, where the shareholders receive a portion of the proceeds based on any sale of GeneRx.

As I have often said, shareholders should view this as an investment in a private company.

Altitrade....What Do You Think Of The Future Of This Company ???

???

Any unofficial updates regarding CRXM?

it s amazing that cannpt get financing to phase 3 soo big market possibilities

I understand CYDY has used AI to come up with additional formulas and indications for leronlimab. Unfortunately I don't think Chris has the money to do anything like that although it could present some options.

3 months or more since I have been aware of the $20m plan. Be nice to hear an update.

Right now Chris should use AI and come up with a list of strong pharmaceutical companies and investors.....The $20,000,000 could be raised easily....Lets replace Nostrum with some good people!

Every conversation I have had with Chris which he can’t say much but I believe he’s doing everything he can to get phase 3 going . We were so close to having phase 3 started with FUJIFILM Diosynth Biotechnologies. If Nostrum didn’t get hammered by the DOJ for up to $50 million we would have been in phase 3 . If Chris gets us trading again and in phase 3 I will retire early from this play . If not I am on Track to working till i am in my grave .

crxm website are active anyways

If the company stays private, there needs to be a way to connect shareholders to buy and sell shares. I owned a shares of stock in a local community bank that was growing its business. The President of the bank had a list of buyers and sellers he would connect. Eventually a link on the banks website allowed shareholders to deal directly with each other.

It would be nice to hear progress details. I'm keeping my fingers crossed CR will be able to put the financing together to move forward with the study. It will be interesting to hear what is in store for CRXM as a company and common shareholders.

I got this feeling we hear something soon .

Hey, BTW, I just saw your private reply post to me from back in May.

I do have the document but I won't share more since I did the super secret handshake. LOL. Perhaps CR will make it available soon.

Do you have a link to the pp? I don’t see it anywhere

So you're saying there's a chance!...YES!

Thanks for posting. Good to see there is still some life and hope for CRXM.

Experienced Leadership & Small Management Team: Gene Bio’s management team is led by Christopher
J. Reinhard, the founder of Gene Bio who has been a driving force responsible for advancing the Generx product
candidate from a pre-clinical lab study at the University of California-San Diego into this current FDA-cleared
Generx Phase 3 clinical study program. Mr. Reinhard was also instrumental in raising over $200 million to lead
and support the Generx development effort. He has also been responsible for three other successful FDA product
registrations.
Nostrum Pharmaceuticals operates multiple manufacturing facilities, supported by sales, marketing and
distribution activities. Nostrum sells generic drug products to hospitals and retail drug stores, by prescription
only, throughout the United States. Nostrum has facilitated the company’s recent financial restructuring and was
responsible for the development of a new Phase 3 clinical plan for FDA registration, and the commercial biologics
manufacturing plan for the Generx product candidate at FujiFilm Bio in Texas.
Nostrum currently owns approximately 75% of Gene Biotherapeutics and approximately 25% is owned by Gene
Bio’s formerly public company shareholders. Following completion of his funding, these shareholders will be
issued contingent value rights (“CVR”) for their proportional share from the net cash distribution entitlements
from the sale of Generx. Gene Bio investors currently own an 85% interest in Generx, and Huapont Life Sciences,
a Chinese-based, publicly traded, pharmaceutical company, owns a 15% equity interest in Generx, and Huapont
Confidential
4
has an exclusive right to manufacture (under certain conditions) market and sell Generx in mainland China
following FDA approval of Generx in the United States.
Nostrum has had some financial setbacks and challenges with its core business, which is why we are now seeking this financial strategic joint venture offering to secure external financial resources to accelerate the clinical developement and commercialization of our Generx product candidate at this time.

Business Strategy: Gene Bio is a small biotechnology research and development boutique, located in San
Diego, that operates with a near-virtual, cost-conserved operating structure. We have a small, highly
experienced team that is currently singularity focused on the successful clinical development and strategic sale
of Generx. This team has worked together on the scientific, medical and clinical development of Generx over the
past 15 years. Set forth below are the key contractors that will be utilized to complete the FDA-cleared Phase 3
Generx study:
(1) FujiFilm Diosynth Biotechnologies: FujiFilm Bio is a world scale operation located in College Park,
Texas. They have expertise in process development and cGMP manufacture of cell and gene therapy
products oncolytic viruses and virial vaccines. We have entered into a manufacturing agreement with
FujiFilm Bio to manufacture Generx supplies for the planned Phase 3 clinical study, and they also have
the current capability to commercially manufacture final Generx product following FDA approval. We
expect that it will take approximately one year to manufacture Generx supplies for the clinical study at an
estimated cost of $5.0 million. In addition, once the final Generx study product is manufactured, Gene
Bio will be required to conduct a preclinical biodistribution study in preparation for the submission of the
Generx Biologics License Application (BLA) with the FDA.
(2) Comac Medical: We are planning to enter into an agreement with Comac Medical, which is located
in eastern Europe, to conduct our final FDA-cleared, Phase 3 clinical study. Comac Medical will be
conducting the study at up to 35 clinical sites, that will include approximately 30 sites in eastern Europe
and Turkey and approximately five sites in the U. S. Based on a recently completed geographic survey,
Comac believes that it is feasible enroll up to all 225 patients during a 12-month recruiting period following
the availability of Generx from FujiFilm Bio. Based on this current plan, we estimate that this clinical
study will cost up to $10.0 million. A copy of this plan, as prepared by Comac Medical, is included in this offering document.

You should reach out to Chris Reinhard and ask for information if you are an accredited investor and have $1 million to invest. The return on investment is amazing. They ae looking to raise $20 million as of the end of May.

It would be great to know how much has been secured and is there an investment banker promoting the deal. If so, who?

How are the current common sharehoders of CRXM going to be treated should a sale happen?

Is CRXM going to stay "private" or get back to trading again and if so, which market?

Still have hope? I’d say it’s a glimmer at best. As far as I understand it, there are a limited number of units for sale with a huge return on investment for those investors should we get approval or a buy out which is what is more likely.

I’m not aware of any units being sold nor what investment bank is shopping it out if any.

I was hoping someone here would provide some updates cause CRXM sure as shit isn’t.

where u get information about that

private placemrnt so webstill have a hope???

Anyone heard anything regarding a newish private placement offering to raise $20M for the Generx Phase 3 study?

Altitrade.....What Is Your Opinion?.....Where Do You Think We Are Headed?

318K shares for sell at eleven cents. Right about my cost average. Prefer to sell all to one investor if possible. This is a modest chunck of my holdings. It is actually in an account I set up for my son a long time ago. Since I had to retire quite early due to health problems from Covid-19, I need to raise money to get him through college.

And if that scenario did play out, I would be the first to join a class action lawsuit against them.

If I have learned anything from this company it is to expect absolutely nothing, because that is exactly what they have given us for many years now. This POS is toast, of that I have no doubt.

And if Reinhardt did buy the company back do you seriously think he will keep it public...or maybe take it private?

We are way overdue for something positive

A month later and still nothing from CRXM.

Thanks JJ24 for reaching him and reporting here. Did he provide anything about how he was going about buying back the company?

Additionally, whoever is funding the buyout beyond Chris, what is their interest in getting the company back to being current in the SEC fikings and trading which is going to have a significant cost. Or do they plan on not being a public traded company?

Then there is the several million dollars needed to fund the trial.

Any idea if CRXM responded to the order?

They have let the website sevices go to shit. Not that they would have posted the info anyway. That would show at least some responsibility on their part to keep investors informed.

https://genebiotherapeutics.com/press/

https://genebiotherapeutics.com/investors/